MyoKardia, a clinical-stage biotech developing therapies for heritable cardiomyopathies, raised $54 million by offering 5.4 million shares at $10.00, below the range of $15 to $17. MyoKardia plans to list on the Nasdaq under the symbol MYOK. Credit Suisse and Cowen & Company acted as lead managers on the deal.
